93 studies found for:    HGFR
Show Display Options
Rank Status Study
1 Completed A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: COMBINED PF-02341066 AND PF-00299804;   Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
2 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met-amplified);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
3 Active, not recruiting Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma
Condition: Gastric Cancer
Intervention:
4 Recruiting Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Conditions: Prostate Cancer;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Gastric Cancer;   Pancreatic Cancer
Interventions: Device: Mesenchymal-marker based ferrofluid (c-MET);   Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid
5 Not yet recruiting Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
Condition: Alcohol Abuse
Interventions: Behavioral: cASBI+cMET;   Behavioral: cASBI
6 Recruiting Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Conditions: Squamous Cell Carcinoma of Head and Neck,;   Metastatic Colorectal Cancer
Interventions: Drug: INC280;   Drug: cetuximab
7 Recruiting A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Condition: Non-small Cell Lung Cancer
Intervention: Drug: INC280
8 Recruiting A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention:
9 Not yet recruiting Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking
Conditions: Alcohol Abuse;   Tobacco Use;   Substance Use
Intervention: Behavioral: cMET
10 Not yet recruiting 11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
Conditions: Primary Hyperparathyroidism;   Tertiary Hyperparathyroidism
Interventions: Radiation: 11C-Methionine PET/CT scanning;   Radiation: 18F-FDG PET/CT scanning;   Radiation: SPECT-CT scanning
11 Recruiting Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: INC280
12 Recruiting INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
Condition: Recurrent Non-small Cell Lung Cancer
Interventions: Drug: INC280;   Drug: erlotinib hydrochloride
13 Active, not recruiting A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
Condition: Solid Tumors
Intervention: Drug: MSC2156119J
14 Completed -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small Cell Lung;   Adenocarcinoma;   Carcinoma, Squamous Cell;   Carcinoma, Large Cell
Intervention: Drug: PF-02341066/PF-00299804
15 Recruiting First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Condition: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Intervention: Drug: MSC2156119J (EMD 1214063)
16 Recruiting Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
Condition: Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Intervention: Drug: INC280
17 Unknown  Study of Tumor Samples From Patients With Lung Cancer
Condition: Lung Cancer
Interventions: Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
18 Active, not recruiting Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib 150mg
19 Recruiting eMet CAR RNA T Cells Targeting Breast Cancer
Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Biological: cMet RNA CAR T cells
20 Recruiting A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
Condition: Cancer
Intervention: Drug: ARGX-111

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years